Company ProfilePremium

Alembic Pharmaceuticals Limited

Company Profile Analysis

Tickers: APLLTD.NS, 533573.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Alembic Pharmaceuticals Limited - Company showcase

Year Founded & Workforce

1907

17,200 Employees

Alembic Pharmaceuticals Limited logo

Alembic Pharmaceuticals Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Alembic Pharmaceuticals Limited Overview

Alembic Pharmaceuticals is a mid-sized, promoter-controlled, vertically integrated Indian generics company with a 119-year group heritage and a deliberately balanced "four-engine" revenue base: India branded formulations (33% of FY26 revenue), US generics (30%), ex-US international generics (20%) and active pharmaceutical ingredients (16%). It ranks 21st in the Indian Pharmaceutical Market with 1.1% share and 17th by prescription volume, anchored by category-leading macrolide brands (Azithral, Althrocin, Roxid) and a fast-growing animal-health franchise. Internationally, it has built one of the deeper ANDA portfolios among Indian mid-caps — 279 filings, 244 approvals and 185 launched US products as of June 2026 — backed by USFDA-inspected oral-solid, oncology, injectable, ophthalmic and dermatology plants in Gujarat. After a 2020–2025 phase of heavy capex and R&D that compressed returns, Alembic is now pivoting to monetisation: accelerated US launches, Paragraph IV first-to-file opportunities, and a nascent US branded women's-health business (Pivya, Nuvessa).


Company self-description. In every 2026 results press release, Alembic describes itself as a vertically integrated research and development pharmaceutical company, active in healthcare since 1907, headquartered in India, which manufactures and markets generic pharmaceutical products worldwide; its research and manufacturing facilities are approved by regulators in multiple developed markets including the USFDA, and it considers itself one of the leaders in branded generics in India [PR-Q4FY26; PR-Q1FY27]. It reports a single operating segment, "Pharmaceuticals" [Q1 FY27 results filing].

Independent characterisation. Functionally, Alembic operates four distinct businesses that share a common R&D and manufacturing backbone:

  1. India Branded Formulations (incl. Animal Health) — prescription-driven branded generics sold through a ~5,500–5,800-strong field force to ~246,000 prescribers [IP-Q1FY27]. The portfolio is roughly 57% "speciality" (chronic and specialist-prescribed therapies such as cardiology, anti-diabetes, gynaecology, ophthalmology, gastro), 21% acute (anti-infectives, cough and cold) and 22% animal health (Q1 FY27 mix) [IP-Q1FY27]. 13% of the portfolio falls under India's National List of Essential Medicines (NLEM) price controls [IP-Q1FY27].

  2. US Generics (and, since March 2026, US Branded) — a direct US front-end (Alembic Pharmaceuticals Inc., New Jersey) selling oral solids, dermatologicals, ophthalmics, injectables (incl. oncology) to wholesalers, retail chains, GPOs. In Q4 FY26, a branded specialty unit, Alembic Therapeutics LLC (Bedminster, NJ), launched Pivya (pivmecillinam) for uncomplicated UTI and in June 2026 acquired Nuvessa (metronidazole vaginal gel 1.3%) [PR-Q4FY26; GlobeNewswire 9 Jun 2026].

  3. Ex-US International Generics — partner-led and, increasingly, own-subsidiary distribution in Europe, Canada, Australia, Brazil, Chile, South Africa, UAE, Southeast Asia (new subsidiaries in Thailand, the Philippines, Germany) and a new Canadian associate (45%) [IP-Q1FY27].

  4. API — merchant sales of active ingredients to customers in 60+ countries, plus captive supply to its own formulations; 152 cumulative US DMFs [IP-Q1FY27].

Revenue model mix. Essentially 100% product sales. Licensing, royalty, service or subscription revenue is not separately disclosed and is immaterial on available evidence. Within product sales, the mix in FY26 was: branded (India + animal health) 33.5%, generic formulations exports 50.4% (US 30.0%, ex-US 20.3%), API 16.2% [PR-Q4FY26].

Value-chain position. Fully integrated from API synthesis (Panelav, Karkhadi) through finished-dose manufacturing (5 USFDA-inspected formulation sites plus a WHO-certified domestic plant at Indore/Pithampur) to front-end marketing in India and the US. In-house bioequivalence (BE) clinical facility at Vadodara supports ANDA filings [Reg30, 13 Jul 2026]. This integration gives cost control and supply security but makes the business capital-intensive (FY26 PP&E INR 34.8 Bn plus CWIP INR 6.3 Bn) [S&P/SA].

Customer types. Indian doctors (prescription influence), distributors/stockists and chemists (India); veterinarians, poultry integrators and livestock farmers (animal health); US wholesalers (consolidated buying groups), retail pharmacy chains, GPOs and specialty pharmacies (US); in-market partners and tender buyers (ex-US); generic formulators globally (API).

End-markets served. Human therapeutics (anti-infective, cardiology, diabetes, gynaecology, gastro, ophthalmology, respiratory/cough-cold, CNS, oncology, dermatology, women's health), veterinary (livestock, poultry, companion animals) and bulk-drug intermediates/APIs.

Strategy

Stated strategy themes (latest disclosures). From the FY26/Q1 FY27 investor materials and management commentary, Alembic's strategy rests on the following stated themes [IP-Q1FY27 "Value Proposition"; PR-Q4FY26; PR-Q1FY27]:

  • Expanding the US product portfolio and evolving the pipeline toward complex platforms and specialty segments (injectables, oncology, ophthalmics, derma, peptides).

  • Building a "focused branded specialty portfolio in the US", beginning with women's health (Pivya, Nuvessa). CFO G. Krishnan has framed this as a "twin engine" alongside generics, in response to persistent generic price pressure [Mint via AskFuzz, May 2026].

  • Developing a specialty drug pipeline for India and growing the India branded business through prescription-led brand building.

  • Exploring opportunities in injectables.

  • Strengthening presence in Canada, South Africa, LATAM and the Middle East; established presence in Chile and UAE.

  • Supplying APIs to 60+ countries with focus on cost efficiency.

  • Maintaining a consistent dividend payout.

  • R&D focused on peptide development and increased ANDA filings [IP-Q1FY27].

Strategic initiatives — last 24 months.

Cost programmes. No formal cost-reduction programme with quantified targets has been announced. Management emphasises operating leverage and API cost efficiency [IP-Q1FY27].

Medium-term financial targets/guidance.

Products & Services

5A. India Branded — Human (Top brands, IQVIA MAT Jun-26) [IP-Q1FY27]

BrandMolecule / therapy (where known)Category rankMarket share (%)
AzithralAzithromycin — anti-infective134.8
Crina-NCRNorethisterone — gynaecology131.7
AlthrocinErythromycin — anti-infective187.8
RoxidRoxithromycin — anti-infective195.1
DeltoneGynaecology/hormonal152.0
GerijointJoint/orthopaedic supplement133.9
Elata—152.4
Cetanil—26.9
Gestofit SRProgesterone — gynaecology218.5
Lactonic—222.9
EstroplusGynaecology/hormonal215.4
Isofit SRIsoxsuprine — obstetrics235.1
TravisightOphthalmology (travoprost family)219.8
UnigolixGynaecology (relugolix combination)213.8
Freego—28.8
WikorylCough & cold combination310.9
IsofitIsoxsuprine35.6
Brozeet-LSRespiratory (levosalbutamol/ambroxol)36.4
UlgelGastro (antacid)37.9
CloffCough preparation311.2
VeldropOphthalmology34.5
Etrik—45.5
Bilambic-MAnti-allergic combination (bilastine/montelukast)45.8
Ovigyn DHGynaecology411.0
TellzyCardiology (telmisartan family)53.8
SharkoferrolHaematinic (human/vet)55.1
BladmirUrology (mirabegron)56.5
Harmoni—55.1
TherapyShare (%)
Animal health22
Anti-infective15
Gynaecology15
Cardiology14
Others11
Anti-diabetic10
Gastrology7
Cough & cold6

Additional facts: five flagship brands exceed INR 1 Bn annual sales; total prescriptions 137.6 Mn (MAT Jun-26) vs 131.3 Mn a year earlier; prescriber base rose from 237,000 to 246,000 [IP-Q1FY27]. Total brands: 208 [IP-Q1FY27].

Therapy mix — India Branded, Q1 FY27 (% of India Branded revenue) [IP-Q1FY27].

New launches: 2 products in Q4 FY26 and 3 in Q1 FY27 [PR-Q4FY26; PR-Q1FY27]. Pricing: MRP-based branded generics; 13% of portfolio under NLEM price control.

5B. India Branded — Animal Health [IP-Q1FY27]

ItemDetail
SegmentsLivestock, poultry, companion animals
LeadershipMarket leader in haematinics and antibiotics
Named brandsSharkoferrol, Moxel, Xceft, Mceft
Brand tiers by annual sales6 brands > INR 300 Mn; 3 brands INR 200–300 Mn; 5 brands INR 100–200 Mn; 26 brands INR 20–100 Mn
Q1 FY27 mixFeed supplement 34%, antibiotic 37%, tonic 10%, supportive therapy 10%, antiparasitic 9%

5C. US Formulations — Generics [IP-Q1FY27]

Dosage formApproved ANDAs
Oral solids164
Dermatology33
Ophthalmic23
Injectable22
Inhalation2
ProductReference brand (RLD)Approval type / dateIQVIA US market sizeNotes / source
Ticagrelor Tablets 60 mgBrilinta (AstraZeneca)Final (2025)Not capturedCardiovascular; cumulative 227 approvals at the time
Macitentan Tablets 10 mgOpsumitFinal (2025)USD 1,180 MnPAH [Simply Wall St summary]
Carbamazepine ER Tablets 100/200/400 mgTegretol-XR (Novartis)Final (2025)Not capturedCNS
Tretinoin Cream 0.025%Retin-AFinal (2025)USD 94 MnDerma
Paroxetine ER Tablets 12.5 mg (sANDA)Paxil CRFinal (~early 2026)Not captured235 approvals at the time
Dapagliflozin Tablets 5/10 mgFarxiga (AstraZeneca)Final, 7 Apr 2026—Eligible for 180-day shared first-to-file exclusivity
Fingolimod Capsules 0.5 mgGilenyaFinal, 25 Apr 2026USD 145 MnMS
Levothyroxine Sodium TabletsSynthroid classFinal, 22 May 2026Not capturedLarge-volume thyroid generic
Haloperidol Tablets 1/2/5/10/20 mgHaldolFinal, 5 Jun 2026USD 27 Mn240 approvals
Larotrectinib Capsules 25/100 mgVitrakvi (Bayer)Tentative, 11 Jun 2026USD 91 MnSole first applicant with Para IV — potential 180-day exclusivity
Tretinoin Cream 0.05%Retin-A (Bausch)Final, 12 Jun 2026Not captured242 approvals
Binimetinib Tablets 45 mg (and earlier 15 mg)MektoviTentative, 19 Jun 2026~USD 26 Mn (reported)Potential 180-day exclusivity
Oseltamivir Phosphate Oral Suspension 6 mg/mLTamifluFinal, 26 Jun 2026Not capturedAntiviral
Dapsone Gel 5%AczoneFinal, 29 Jun 2026Not captured244 approvals
Prucalopride Tablets 1/2 mgMotegrity (Takeda)Final, 28 Jul 2026USD 100 Mn245 approvals
Ciprofloxacin/Dexamethasone Otic Suspension 0.3%/0.1%CiprodexFinal, ~Oct 2026Not capturedLatest approval [EquityBulls, Oct 2026]
Methotrexate Injection USP—Final (2026)Not capturedInjectables
Diltiazem HCl TabletsCardizem (Bausch)Final (2025–26)Not capturedCardiovascular
Olaparib Tablets 100/150 mg (partner NATCO)LynparzaTentative to partner, 18 Jul 2026Not capturedAlembic to market in US per reports

Approved ANDAs by dosage form (cumulative, June 2026; total 244 incl. 20 tentative).

Cumulative: 279 ANDA filings, 244 approvals, 185 products launched; 7 launches in Q1 FY27; 15+ launches guided for FY27 [IP-Q1FY27]. In July 2025 the US unit described its portfolio as 160+ molecules and 413 products (SKUs) [Craig Salmon statement, Jul 2025].

Notable US approvals, Jan 2025 – Oct 2026 (product by product).

Earlier anchor products include aripiprazole (2015 launch), lamotrigine ER (2024, USD 163 Mn), paliperidone ER (2024, USD 48 Mn), bosentan, deferasirox, pantoprazole injection, doxorubicin injection and bromfenac ophthalmic.

5D. US Formulations — Branded (Alembic Therapeutics LLC)

ProductDescriptionStatusPricing
Pivya (pivmecillinam) tabletsFirst-line oral antibiotic for uncomplicated UTI in adult women; FDA-approved April 2024; acquired with Utility TherapeuticsCommercial launch Q4 FY26 (March 2026); management reported a completed "soft launch" with encouraging response [IP-Q1FY27]—
MEC (mecillinam, IV)Under development for complicated UTIDevelopment; timeline not disclosed—
Nuvessa (metronidazole vaginal gel 1.3%)Single-dose pre-filled applicator, ~5 g gel with 65 mg metronidazole, for bacterial vaginosis in females ≥12 years; acquired from Exeltis USAAcquired 9 Jun 2026; sold via retail and specialty pharmacyTerms and price not disclosed

5E. Ex-US Formulations

Product-level detail is not publicly disclosed. Operations run through partnerships in Europe, Canada, Australia, Brazil, Chile and South Africa, with own presence in Chile and the UAE and new subsidiaries in Thailand, the Philippines, Germany and Dubai [IP-Q1FY27; Reg30].

5F. API

152 cumulative US DMFs (3 filed in Q1 FY27, 2 in Q3 FY26) [IP-Q1FY27; IP-Q3FY26]. Molecule-level catalogue is not publicly disclosed in reviewed documents.

Financial Narrative

All consolidated. Primary source for FY22–FY26 line items: [S&P/SA] standardised from company filings, cross-checked to company press releases and the Q1 FY27 investor presentation. Where company-reported figures differ, both are shown.

6A. Income statement: notes and sources

Notes: Company-reported EBITDA for FY22 is not available in reviewed company decks (entered as 0 = not disclosed in this row; do not chart). FY23 company EBITDA (INR 7.79 Bn) and company net profit (INR 4.97 Bn) exclude the one-time Aleor write-off; S&P net income for FY23 is INR 3.42 Bn — a discrepancy of ~INR 1.55 Bn attributable to that adjustment [IP-Q1FY27 note]. FY26 pre-tax income includes ~INR 670 Mn of unusual/exceptional charges [S&P/SA]; Q4 FY26 alone carried a INR 0.25 Bn exceptional item and a deferred-tax credit of INR 1.14 Bn [IP-Q1FY27; FPJ, May 2026].

6B. Margins (%)

Revenue CAGR FY22–FY26: 8.5% (INR 53.06 Bn → 73.45 Bn). Net income CAGR FY22–FY26: 6.7%. Revenue TTM (Jun 2026): INR 77.84 Bn, +14.1% [S&P/SA].

Note on gross margin: S&P's gross margin (~72%) treats only material cost as cost of revenue; company decks show gross margin of 76% (Q1 FY26), 71% (Q4 FY26) and 71% (Q1 FY27) — the Q1 FY27 compression reflects a 52% YoY jump in material consumption as US volume launches and API mix rose [IP-Q1FY27].

6C. Balance sheet: notes and sources

Notes: FY22 short-term borrowings include INR 2,000 Mn current portion of long-term debt. S&P reports nil intangibles for FY23–FY25 (company may carry small intangibles within PP&E); FY26 intangibles of INR 2,868 Mn principally reflect Utility Therapeutics/Pivya, which the company accounted as an intangible-asset acquisition of USD 25 Mn [PR-Q2FY26 via FilingReader] — note the discrepancy with the USD 12 Mn headline consideration (headline excludes contingent/profit-share components). CRISIL reported liquid surplus of INR 203 Cr at 31 Mar 2026 and 27% average utilisation of fund-based limits over the six months to March 2026 [CRISIL-Jun26].

6D. Cash flow

Company-reported capex (INR Bn): FY23 4.12, FY24 3.45, FY25 5.75, FY26 4.32 [IP-Q1FY27] — consistent with S&P cash capex within ±5%.

6E. Ratios

Methodology: working-capital days computed as year-end balance ÷ revenue × 365 (revenue basis used because S&P's material-only cost of revenue would inflate inventory days to >400). Ratios from [S&P/SA] unless computed. Company ROCE FY22 not disclosed (0 = not available).

6F. Commentary — trends, inflections and drivers

Revenue. Growth has been steady but unspectacular: an 8.5% four-year CAGR, with FY22 (−1.6%) and FY23 (+6.5%) depressed by US price erosion and a COVID-era high base in acute domestic products, then a re-acceleration to 10.2% in FY24 and 10.1% in FY26. The decisive inflection is Q1 FY27: +26% YoY to INR 2,150 Cr, driven by US formulations (+49%), API (+33%) and ex-US (+17%) [PR-Q1FY27]. TTM revenue of INR 77.8 Bn implies the business is now running ~6% ahead of FY26.

Profitability. The FY23 trough (EBIT margin 7.7%) reflected high R&D (12.8% of sales), under-utilised new plants (oncology, injectables, derma) and the Aleor write-off. FY24 recovery came largely from a sharp R&D cut (from INR 7.2 Bn to 4.8 Bn). Since then, EBITDA margins have been stuck in a 15–16% band as R&D was rebuilt (9.6% of FY26 sales) and the US branded launch absorbed SG&A. Pre-R&D EBITDA margin was 25% in Q4 FY26 and 24% in Q1 FY27 [PR-Q4FY26; PR-Q1FY27], indicating the underlying generic engine earns healthy contribution; post-R&D margin was 16% in Q1 FY27 (vs 17% Q1 FY26) as material costs outpaced revenue. Net income growth in FY26 (+15.7%) was flattered by an unusually low tax rate (3.3%), including a INR 114 Cr Q4 deferred-tax credit; on a normalised ~17–18% tax rate, FY26 net income would have been roughly INR 5.7 Bn — essentially flat on FY25. This is the single most important quality-of-earnings caveat.

Balance sheet. Leverage rose meaningfully in FY25: net debt nearly tripled to INR 11.7 Bn as inventory jumped INR 6.4 Bn (stocking ahead of US launches) and receivables rose INR 3.8 Bn; CRISIL explicitly flagged inventory build-up for launches and expected liquidation in FY26 [CRISIL Jul-2025]. FY26 delivered only partial normalisation — inventory still rose INR 2.2 Bn and net debt edged up to INR 12.3 Bn — though net debt/EBITDA improved to 1.12x. The debt is almost entirely short-term (commercial paper and working-capital lines), so refinancing risk is real but mitigated by the AA+/A1+ rating and promoter strength.

Cash flow. FY25 was an outlier year of negative FCF (−INR 4.8 Bn) because of the working-capital build; FY26 FCF recovered to INR 3.5 Bn (FCF/net income 52%). Over five years cumulative FCF (INR 7.6 Bn) covered only ~72% of cumulative dividends (INR 10.6 Bn), with the gap debt-funded — sustainable at current leverage but not indefinitely.

Returns. ROE in the 11–13% range and ROIC of ~11–12% are below large-cap Indian peers and only modestly above cost of capital, reflecting a heavy fixed-asset base (asset turnover <1x). Company-reported ROCE excluding non-deployed assets (15%) suggests idle capacity still burdens reported returns; incremental US launches from existing plants offer operating leverage.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Lines

Business lineContentsKey products / platforms

India Branded Business

Human branded generics (speciality + acute) and Animal Health

Azithral, Althrocin, Roxid, Wikoryl, Gestofit, Isofit, Travisight; Sharkoferrol, Moxel, Xceft, Mceft (vet)

US Formulations

US generics (oral solid, derma, ophthalmic, injectable, oncology) and US branded (Pivya, Nuvessa)

185 commercialised generics; 244 ANDA approvals

Ex-US Formulations

Generics in Europe, Canada, Australia, Brazil, Chile, South Africa, UAE, SE Asia

Partner and subsidiary-led

API

Merchant APIs and intermediates

152 US DMFs; customers in 60+ countries

Business Lines (Annual)

Business lineFY2022FY2023FY2024FY2025FY2026

India Branded Business (INR Cr)

1,9262,0632,2002,3392,458

US Formulations (INR Cr)

1,6661,5721,7301,9572,206

Ex-US Formulations (INR Cr)

7758521,0521,2431,494

API (INR Cr)

9391,1661,2461,1331,187

Total Revenue from Operations (INR Cr)

5,3065,6536,2286,6727,345

Business Lines (FY2023–FY2026)

Business lineFY2023FY2024FY2025FY2026

India Branded growth (%)

7.16.66.35.1

US Formulations growth (%)

-5.610.113.112.7

Ex-US Formulations growth (%)

9.923.518.220.2

API growth (%)

24.26.9-9.14.8

Total growth (%)

6.510.27.110.1

Business Lines (FY2024–FY2026)

Business lineFY2024FY2025FY2026

India Branded share (%)

35.335.133.5

US Formulations share (%)

27.829.330.0

Ex-US Formulations share (%)

16.918.620.3

API share (%)

20.017.016.2

Business Lines (Quarterly)

Business lineQ1FY26Q2FY26Q3FY26Q4FY26Q1FY27

India Branded (INR Cr)

599639652568642

US Formulations (INR Cr)

523566554564778

Ex-US Formulations (INR Cr)

328392406369383

API (INR Cr)

261314264347346

Total (INR Cr)

1,7111,9111,8761,8482,150

Revenue by Segment

MetricFY2022FY2023FY2024FY2025FY2026

Animal Health revenue (INR Mn)

2,3202,8063,5534,3055,191

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Mn)

53,05856,52662,28666,72173,449

Gross profit (INR Mn)

38,07638,77844,32547,91252,660

Operating income / EBIT (INR Mn)

5,8754,3786,6077,2987,970

EBITDA — S&P basis (INR Mn)

8,5856,9629,1419,89110,978

EBITDA — company reported (INR Mn)

07,7909,61010,53011,770

Pre-tax income (INR Mn)

6,2543,5466,3187,0726,940

Income tax (INR Mn)

1,0451261601,252231

Net income attributable (INR Mn)

5,2093,4206,1585,8346,748

EPS basic (INR)

26.5017.4031.3329.6834.33

EPS diluted (INR)

26.5017.4031.3329.6834.33

Dividend per share (INR)

108111112

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

71.868.671.271.871.7

Operating (EBIT) margin (%)

11.17.710.610.910.9

EBITDA margin S&P basis (%)

16.212.314.714.814.9

EBITDA margin company reported (%)

014151616

Net margin (%)

9.86.19.98.79.2

Effective tax rate (%)

16.73.62.517.73.3

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Mn)

71,22061,82864,45677,72987,626

Cash and equivalents (INR Mn)

6117551,2028351,964

Short-term borrowings (INR Mn)

6,3006,3594,30511,95612,389

Long-term borrowings (INR Mn)

00001,219

Lease liabilities (INR Mn)

871862827619691

Total debt incl. leases (INR Mn)

7,1717,2205,13212,57514,299

Net debt (INR Mn)

6,5606,4653,93011,74012,336

Shareholders' equity (INR Mn)

52,37643,70548,18251,89556,690

Goodwill and intangibles (INR Mn)

1,5480002,868

Inventory (INR Mn)

16,09714,75316,43522,88125,106

Trade receivables (INR Mn)

8,07110,46410,24813,99814,663

Trade payables (INR Mn)

7,0646,7987,3568,7998,351

Working capital (INR Mn)

11,44312,73116,23616,75519,788

Capital work-in-progress (INR Mn)

22,0586,0135,2448,3726,337

Book value per share (INR)

266.46222.34245.12264.09288.70

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Mn)

5,5247,2408,0328807,827

Capital expenditure (INR Mn)

4,2564,4343,2755,6364,346

Free cash flow (INR Mn)

1,2672,8054,757-4,7573,481

Dividends paid (INR Mn)

2,7521,9661,5732,1622,162

Share buybacks (INR Mn)

00000

Change in working capital (INR Mn)

-3,673-576-957-9,214-2,568

Intangibles purchased (INR Mn)

0000603

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE (%)

10.17.113.411.612.4

ROA (%)

5.34.16.56.46.0

ROIC (%)

8.77.712.610.411.6

ROCE S&P (%)

10.99.613.213.612.9

ROCE company, ex non-deployed assets (%)

014151615

Current ratio (x)

1.671.782.121.701.76

Debt / equity (x)

0.140.170.110.240.25

Net debt / EBITDA (x)

0.760.930.431.191.12

Interest coverage EBIT/interest (x)

33.18.711.89.38.5

Asset turnover (x)

0.770.850.990.940.89

Receivable days (revenue basis)

55.567.660.176.672.9

Inventory days (revenue basis)

110.795.396.3125.2124.8

Payable days (revenue basis)

48.643.943.148.141.5

Cash conversion cycle (revenue basis, days)

117.6119.0113.3153.7156.2

Dividend payout (cash basis, %)

52.857.525.537.132.0

Revenue by Region

RegionFY2024FY2025FY2026

India — branded formulations (INR Cr)

2,2002,3392,458

United States — formulations (INR Cr)

1,7301,9572,206

Rest of World — formulations (INR Cr)

1,0521,2431,494

Global API — India + export (INR Cr)

1,2461,1331,187

Region Margins & Growth (%)

RegionFY2024FY2025FY2026

India branded growth (%)

6.66.35.1

United States growth (%)

10.113.112.7

Rest of World growth (%)

23.518.220.2

Global API growth (%)

6.9-9.14.8

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025FY2026

Closing share price (INR)

696.10473.08949.00906.05653.53

Market capitalisation (INR Mn)

145,77197,564193,575182,755130,370

Enterprise value (INR Mn)

151,109104,548200,785192,124143,795

P/E (x)

27.9828.5331.4331.3319.32

EV/EBITDA (x)

17.6015.0221.9719.4213.10

EV/Sales (x)

2.851.853.222.881.96

P/B (x)

2.782.234.023.522.30

Dividend yield (%)

1.441.691.161.211.84

Share Price & Returns

HorizonReturnBasis / source

Since FY26 year-end (31 Mar 2026)

~+23% (653.53 → ~803)

Computed

1 year

~−13% to −20% (reported mid-2026 readings)

Bajaj Broking; EquityPandit (14 Jul 2026)

~3.5 years (since 31 Mar 2023)

~+70% (473.08 → ~803)

Computed

~4.5 years (since 31 Mar 2022)

~+15% (696.10 → ~803)

Computed

Per-Share Data and Dividends & Capital Returns

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

108111112

Dividends paid in following year (INR Mn)

19661,5732,1622,1622,360

Credit Ratings

AgencyInstrumentRatingOutlookDate

CRISIL

Long-term bank facilities (INR 1,100 Cr)

AA+

Stable

30 Jun 2026

CRISIL

Commercial paper (INR 1,100 Cr)

A1+

—

30 Jun 2026

CARE

Commercial paper

A1+

—

Per CP offer document (Dec 2025)

Moody's / S&P / Fitch

—

Not rated

——

Analyst Conclusions

Management guidance (FY27). Consolidated revenue growth in the mid-teens (raised from 10–12%); US generics growth mid-to-high teens (raised from low teens); 15+ US launches; R&D ~9–10% of revenue; continued investment in US branded and peptide pipeline [IP-Q1FY27; Q1 FY27 call].

Implied FY27 revenue on guidance: ~INR 8,350–8,450 Cr (mid-teens on INR 7,345 Cr).

Bull case.

  1. US launch super-cycle on existing capacity. Q1 FY27 US revenue +49% with 7 launches, 15+ guided for the year, plus Para IV exclusivities (Larotrectinib, Binimetinib, Dapagliflozin) should lift utilisation of plants built in 2020–23, driving EBITDA margins from 16% toward pre-R&D-leveraged high-teens.

  2. Re-rating from trough multiples. At 20x forward earnings and 15x EV/EBITDA, the stock trades at roughly half the Indian pharma median multiple despite AA+ credit, a 1.5% yield and accelerating growth; sustained mid-teens growth could close part of that gap.

  3. Compliance overhang removed. EIRs across key sites and a zero-483 unannounced BE inspection (Sep 2026) reduce the tail risk that has historically de-rated Indian generic names.

Bear case.

  1. Earnings quality and normalised growth. FY26 PAT growth of 16% relied on a 3.3% tax rate and a INR 114 Cr deferred-tax credit; at normal tax, FY26 earnings were flat, and Q1 FY27 PAT grew only 12% on 26% revenue growth as margins compressed.

  2. Working capital and leverage. Inventory of INR 25.1 Bn (~125 days of sales) and ~INR 12.4 Bn of short-term debt mean US launch growth could again consume cash, as in FY25 (FCF −INR 4.8 Bn).

  3. Structural India underperformance and US branded risk. India Branded is growing ~3 points below the market with share slipping; the US branded foray is tiny and SG&A-hungry, with limited evidence of commercial traction yet.

Key catalysts and monitorables (next 12 months).

Analyst verdict. Alembic Pharmaceuticals enters the second half of FY27 at a genuine operational inflection, but the investment case still hinges on converting revenue momentum into cash and margin. The evidence for the inflection is strong: Q1 FY27 revenue grew 26%, US formulations 49% and API 33%; management raised full-year guidance to mid-teens growth; and the regulatory slate is unusually clean after EIRs at the Karkhadi injectables plant and a zero-observation unannounced inspection of the BE centre that had drawn a July warning letter. A portfolio of 244 ANDA approvals, three oncology/diabetes exclusivity opportunities and 15+ planned US launches give the generic engine visible fuel, and much of the capacity needed to serve it has already been built and paid for.

The counter-evidence is equally concrete. Reported FY26 profit growth was tax-assisted; post-R&D EBITDA margins have not moved beyond 16% in three years; the cash conversion cycle has widened by roughly 40 days since FY24; and almost all borrowings are short-term. India — historically the cash cow — is growing below the market and ceding share, while the US branded venture is too small to move consolidated numbers for at least several quarters and will weigh on SG&A in the interim.

Net, Alembic screens as a reasonably priced, credit-strong, promoter-anchored mid-cap whose discount to sector multiples reflects legitimate concerns about returns (ROIC ~11–12%) rather than mispricing alone. The risk-reward is constructive if — and only if — the next two to three quarters demonstrate operating leverage (EBITDA margin expanding toward 18%), positive free cash flow despite launch inventory, and stabilisation of India share. Investors should treat Q2–Q3 FY27 gross margin, inventory days and Pivya/Nuvessa traction as the decisive tests; a pass on all three would support a re-rating, while a miss on cash conversion would confirm the "growth without returns" pattern of FY22–FY26.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleOn board sinceBorn / ageBackgroundCommittees

Chirayu R. Amin

Executive Chairman (CEO until 31 Mar 2026); promoter

16 Jun 2010 (re-appointed 1 Apr 2021)

4 Dec 1946 / 79

MBA (USA); directorships in Alembic Ltd, Paushak Ltd, Shreno Ltd, Nirayu Ltd

—

Pranav C. Amin

Managing Director (heads international business)

31 Mar 2011; MD since 2016

5 Oct 1975 / 51

—

SRC member; RMC member

Shaunak C. Amin

Managing Director (heads India Branded Business)

2 May 2013

1 May 1978 / 48

——

Raj Kumar Baheti

Non-Executive Non-Independent Director (from 1 Apr 2026; earlier Executive Director and CFO)

16 Jun 2010

24 Oct 1959 / 66

Commerce graduate; Fellow, ICAI

SRC member; RMC member

Ashok Kumar Barat

Independent Director

10 Feb 2022

5 Dec 1956 / 69

Holds 7 listed directorships

Audit Committee Chair (from 4 Feb 2025); RMC Chair; NRC member

Jai Shishir Diwanji

Independent Director

5 May 2023

4 Feb 1973 / 53

5 listed directorships

SRC Chair; Audit and NRC member

Manish S. Kejriwal

Independent Director

31 Mar 2024

8 Nov 1968 / 57

Private equity investor; company profile describes co-chairing CII's PE/VC committee and SEBI alternative investments advisory role

NRC Chair (from 4 Feb 2025)

Geeta A. Goradia

Independent Director

3 Feb 2025

19 Sep 1953 / 73

Prior independent directorships incl. Panasonic Energy India

Audit and NRC member

Sujit J. Bhayani

Independent Director

18 Jun 2026 (5-year term)

——

Not yet disclosed

“—” = not publicly disclosed.

Executive Leadership Team

NameTitleSinceNotes

G. Krishnan

Chief Financial Officer

7 Jul 2025

Succeeded R.K. Baheti as CFO [FY26 Directors' Report]

Chirag Shukla

Company Secretary & Compliance Officer

20 Aug 2026

Replaced Manisha Saraf (resigned 10 Aug 2026)

Tushar Mehta

Head – R&D

3 Jun 2026

New appointment

Ramesh Juneja

Senior Management Personnel

1 Jun 2026

Role not specified in filing

Ajay Kumar Desai

SVP – Finance

—

IR contact on FY26 release

Craig Salmon

President, Alembic Pharmaceuticals Inc. (US)

—

Leads US business

Dr. Sachin Ghosalkar

SVP – Supply Chain & Operations

—

RMC invitee

Ish Bansal

Head – Business Development

—

RMC invitee

Isha Lamba

Investor Relations

—

IR contact

Executive Leadership Team (Annual)

ExecutiveFY2024 total (INR Mn)FY2025 total (INR Mn)

Chirayu R. Amin

193.8141.0

Shareholding Trend

Holder categoryJun-2025Sep-2025Dec-2025Mar-2026Jun-2026

Promoters (%)

69.6869.7469.7469.7469.87

Mutual funds (%)

9.058.558.228.188.73

Foreign institutions (%)

3.964.054.244.254.17

Other domestic institutions (%)

7.417.757.958.007.20

Retail and others (%)

9.909.929.859.8310.03

Major Shareholders

HolderStake (%)TypeSource

Nirayu Pvt Ltd

35.65

Promoter

MarketsMojo, Jun 2026

Alembic Ltd

28.54

Promoter

ICRA rationale on Alembic Ltd, Aug 2026

Life Insurance Corporation of India

4.32

Institution

MarketsMojo, Jun 2026

Chirayu R. Amin (direct)

~2.55

Promoter/insider

Simply Wall St

Alembic City Ltd

—

Promoter group

Trendlyne list

DSP Midcap Fund

—

Mutual fund

MarketsMojo list

Kotak Small Cap Fund

—

Mutual fund

MarketsMojo list

ICICI Prudential Pharma Healthcare & Diagnostics Fund

—

Mutual fund

MarketsMojo list

Tata AIA Life (Unit Linked Multi Cap)

—

Insurance

MarketsMojo list

141–179 FIIs combined

~4.2

Foreign

MarketsMojo / Trendlyne

Competitive Landscape

Competitors by Segment

BusinessCompetitors (named)

India branded (human)

Sun Pharma, Cipla, Mankind Pharma, Torrent Pharma, Lupin, Zydus Lifesciences, Alkem Laboratories, Abbott India, Intas (unlisted), Macleods (unlisted), Ipca, Ajanta, Glenmark

India animal health

Zoetis, Elanco, Virbac, MSD Animal Health, Indian Immunologicals (most unlisted in India)

US generics

Aurobindo, Zydus, Lupin, Dr. Reddy's, Sun Pharma, Glenmark, Torrent, Cipla, Teva, Viatris, Amneal, Hikma

Ex-US generics

Aurobindo, Torrent (Brazil), Glenmark, Sandoz, Teva and local players

API

Divi's, Aurobindo, Ipca, Granules, Laurus, Chinese API producers

US branded women's health/UTI

Branded and generic anti-infective makers; Exeltis; others (not exhaustively verified)

Peer Comparison FY2026

CompanyFY26 revenue (INR Cr)YoY growth (%)Notes

Sun Pharma

58,46211.2

Largest Indian pharma

Aurobindo Pharma

33,6536.1

US generics heavy

Zydus Lifesciences

27,65819.0—

Torrent Pharma

13,98021.4

Incl. JB Pharma consolidation

Ipca Laboratories

9,6467.9

Closest India/API peer

Alembic Pharmaceuticals

7,34510.1

Subject

Ajanta Pharma

5,45317.3

Branded EM peer

Peer Comparison FY2026 — Revenue

MetricAlembicTorrent PharmaIpca LabsAjanta Pharma

Revenue (INR Cr)

7,34513,9809,6465,453

Revenue growth (%)

10.121.47.917.3

EBITDA margin (%)

16.032.6——

Net margin (%)

9.215.3——

R&D intensity (%)

9.6———

P/E (x, snapshot)

23.277.639.239.9

Company Snapshot

$848.1M

Revenue

17,200

Employees

1907

Founded

Vadodara, India

Headquarters

SWOT Analysis

Strengths

  • Diversified revenue: no single business exceeds 34% of FY26 revenue (India 33.5%, US 30.0%, ex-US 20.3%, API 16.2%) [PR-Q4FY26].
  • Large regulatory moat for its size: 279 ANDA filings, 244 approvals, 185 launches, 152 DMFs (Jun 2026) [IP-Q1FY27].
  • Category-leading domestic brands: Roxid 95.1% and Althrocin 87.8% share; 5 brands above INR 1 Bn [IP-Q1FY27].
  • Animal health growing at 22% CAGR (INR 2.32 Bn → 5.19 Bn, FY22–FY26) [IP-Q1FY27].
  • Clean recent compliance: EIRs for F3 (May 2026) and multiple 2024–25 inspections; zero-483 unannounced BE inspection (Sep 2026) [IP-Q1FY27; Reg30].
  • Strong credit and promoter support: CRISIL AA+/Stable; promoters 69.87% with zero pledge [CRISIL-Jun26; Jun-26 SHP].

Weaknesses

  • Below-market India growth: India Branded +5.1% in FY26 vs IPM ~8%; share slipped to 1.1% [PR-Q4FY26; IP-Q1FY27].
  • Modest margins: FY26 EBITDA margin 16% vs Torrent ~33% [IP-Q1FY27; Torrent data].
  • Working-capital intensity: cash conversion cycle ~156 days in FY26 vs ~113 days in FY24; inventory INR 25.1 Bn [S&P/SA].
  • Earnings quality: FY26 effective tax rate 3.3% including a INR 114 Cr deferred-tax credit; normalised PAT growth ~flat [S&P/SA; FPJ].
  • Mid-level returns: ROE 12.4%, ROIC 11.6% (FY26) [S&P/SA].
  • Governance concentration: executive chair and both MDs from one family; no CEO post since April 2026 [GOV-Mar26].

Opportunities

  • FY27 guidance raised to mid-teens growth after Q1 revenue +26% [Q1 FY27 call].
  • Para IV exclusivity: Larotrectinib (sole FTF, USD 91 Mn), Binimetinib, Dapagliflozin (shared) [Reg30].
  • US branded women's health platform (Pivya + Nuvessa) with management targeting franchise expansion [PR-Q4FY26; CFO commentary].
  • 15+ US launches in FY27 from existing capacity — operating leverage on underutilised assets (company ROCE ex-non-deployed assets 15% vs reported ~13%) [IP-Q1FY27].
  • RoW expansion via own subsidiaries (Germany, Dubai, Thailand, Philippines) and Canada JV [IP-Q1FY27].
  • Peptides and injectables where competition is thinner [IP-Q1FY27].

Threats

  • US price erosion — FY23 US revenue fell 5.6% [IP-Q1FY27].
  • Regulatory risk: July 2026 Warning Letter at BE site (to investigator) and Feb 2026 two-observation 483 at F3 show continuing scrutiny [Reg30; TradeBrains].
  • API volatility: FY25 API revenue −9.1% [IP-Q1FY27].
  • Domestic price controls (13% NLEM) and competitive intensity in acute therapies [IP-Q1FY27].
  • Execution risk in US branded: Pivya's commercial ramp is unproven; branded launches require sustained SG&A [CFO commentary].
  • Refinancing exposure: ~87% of debt is short-term (INR 12.4 Bn of INR 14.3 Bn) [S&P/SA].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 2025FY25 results; dividend INR 11/shareFY25 net income −5% on higher tax; inventory build
12 Jun 2025CRISIL reaffirms AA+/A1+; CP programme enhanced to INR 1,100 CrFunding headroom for launches
2–3 Jul 2025Acquisition of Utility Therapeutics (~USD 12 Mn)Entry into US branded market
7 Jul 2025G. Krishnan appointed CFOFinance leadership change
25 Jul 2025CRISIL reaffirms; bank lines raised to INR 800 CrLiquidity
Aug 2025Q1 FY26: revenue INR 1,711 Cr (+10%), PAT INR 154 Cr (+14%)Steady start
4 Nov 2025Q2 FY26: revenue INR 1,910 Cr (+16%), PAT INR 185 Cr (+20%), EBITDA margin 17%; 6 ANDA approvalsStrongest FY26 quarter
12 Jan 2026USFDA tentative approval for an oncology product (company already held final approval for Bosutinib 100/500 mg)Oncology pipeline
5 Feb 2026Q3 FY26: revenue INR 1,876 Cr (+11%), EBITDA margin 16%, PAT INR 133 CrEx-US +36%; Pivya on track
Feb 2026USFDA inspection of F3 Karkhadi injectables/ophthalmic: Form 483 with 2 observationsCompliance monitorable
Mar 2026Pivya commercial launch via Alembic TherapeuticsUS branded entry executed
20 Mar 2026Exit of 16.18% RIGImmune stakePortfolio clean-up
23 Mar 2026Stock hits 52-week low of INR 635.80Sentiment trough
1 Apr 2026Chirayu Amin relinquishes CEO role; Baheti becomes non-executiveLeadership transition
7 Apr 2026Dapagliflozin final approval with 180-day shared exclusivityNear-term US upside
23 Apr 2026German subsidiary incorporatedEurope front-end
25 Apr 2026Fingolimod capsules approval (USD 145 Mn market)CNS addition
13 May 2026EIR received for F3 injectable facilityRemoves overhang
15 May 2026Q4/FY26 results: revenue INR 7,345 Cr (+10%), PAT INR 675 Cr (+16%); dividend INR 12 recommendedFY26 close
22 May 2026Levothyroxine sodium tablets final approvalVolume product
1–3 Jun 2026Ramesh Juneja appointed SMP; Atul Suri exits; Tushar Mehta named Head R&DManagement reshuffle
5 Jun 2026Haloperidol tablets approvalPortfolio filler
6 Jun 202645% Canada JV agreementRoW expansion
9 Jun 2026Nuvessa acquisitionUS branded scale
11 Jun 2026Larotrectinib TA (sole FTF; USD 91 Mn)Exclusivity opportunity
12 Jun 2026Tretinoin cream 0.05% final approvalDerma
18 Jun 2026Sujit Bhayani appointed independent directorBoard refresh
19 Jun 2026Binimetinib 45 mg TAExclusivity opportunity
26–29 Jun 2026Oseltamivir suspension and Dapsone gel 5% approvalsPortfolio breadth
30 Jun 2026CRISIL reaffirms AA+/Stable; bank lines raised to INR 1,100 CrCredit stability
13 Jul 2026Disclosure of USFDA Warning Letter (dated 10 Jul) to clinical investigator at BE facility; ICF observation, no data-integrity issue, no operating restriction; stock −1.5% to −2%Regulatory headline risk
18 Jul 2026Partner NATCO receives Olaparib TAOncology partnership
28 Jul 2026Prucalopride tablets final approval (USD 100 Mn)GI addition
29 Jul 2026Record date for INR 12 dividendShareholder return
4 Aug 2026Q1 FY27: revenue INR 2,150 Cr (+26%), PAT INR 173 Cr (+12%), pre-R&D EBITDA INR 523 Cr; guidance raisedGrowth inflection
5 Aug 202616th AGMDividend approved
5 Aug 2026Brokerage target-price upgrades after Q1 (ICICI Securities named among upgrades)Sell-side sentiment improves
10 / 20 Aug 2026CS Manisha Saraf resigns; Chirag Shukla appointedCompliance office change
24 Aug 2026Dubai subsidiary (Alembic Pharmaceuticals Global FZCO) incorporatedMENA hub
31 Aug–10 Sep 2026Unannounced USFDA BE-facility inspection: zero 483 observationsNeutralises July warning-letter overhang
1–2 Sep 2026Investor/analyst meetingsIR outreach
4 Sep 2026FY26 dividend payment date—
11 Sep 2026INR 150 Cr commercial paper redeemed on maturityLiquidity management
~17–18 Oct 2026Ciprofloxacin/Dexamethasone otic suspension final approvalLatest approval

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment (FY2022–FY2026): Total Revenue from Operations rose from INR 53,060 Mn in FY2022 to INR 73,450 Mn in FY2026.
Alembic Pharmaceuticals Limited — Revenue by Segment (FY2022–FY2026)
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Total Revenue from Operations53,06056,53062,28066,72073,450
India Branded Business19,26020,63022,00023,39024,580
US Formulations16,66015,72017,30019,57022,060
Ex-US Formulations7,7508,52010,52012,43014,940
API9,39011,66012,46011,33011,870
Animal Health revenue2,3202,8063,5534,3055,191

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Alembic Pharmaceuticals press release, Q1 FY27 results, 4 Aug 2026 — alembicpharmaceuticals.com/webfiles/media/2026-2027/press-release-june-2026.pdf
  2. Investor Presentation Q1 FY27, filed with NSE 4 Aug 2026 — nsearchives.nseindia.com/corporate/APLLTD_04082026141335_Intimation_Investors_Presentation_S.pdf
  3. Press release, audited FY26 results, 15 May 2026 — nsearchives.nseindia.com/corporate/APLLTD_15052026145334_Intimation_Press_Releases_F_Signed.pdf
  4. Press releases Q2 FY26 (4 Nov 2025) and Q3 FY26 (Feb 2026): Q3 FY26 investor presentation (5 Feb 2026)
  5. Integrated Governance filing for FY26, NSE, 30 Apr 2026
  6. Regulation 30 intimation on USFDA Warning Letter, 13 Jul 2026 — alembicpharmaceuticals.com
  7. CRISIL rating rationales, 30 Jun 2026 and 25 Jul 2025; company credit-rating intimation, 1 Jul 2026
  8. ICRA rationale on Alembic Ltd, 31 Aug 2026 (promoter stake)
  9. S&P Global Market Intelligence data via StockAnalysis.com (income statement, balance sheet, cash flow, ratios), updated 4 Aug 2026
  10. GlobeNewswire release on Nuvessa acquisition, 9 Jun 2026
  11. PTI / Indian Pharma Post / Business Standard coverage of Utility Therapeutics acquisition, Jul 2025
  12. Medical Dialogues, FilingReader, Angel One, Free Press Journal, Kotak Neo, Trendlyne, Upstox, MarketsMojo, Univest, Sahi, Business Standard, The Machine Maker, EquityBulls coverage (2025–2026)
  13. Pharmarack data via BioSpectrum India and Asianet (IPM size and growth, 2025–2026): IQVIA India quarterly insights Q2 2025
  14. Torrent Pharma FY26 results; craytheon.com pharmaceutical sector table (peer revenue and P/E)
  15. Simply Wall St (executive compensation and consensus snapshots)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.